天津医药

• 心血管疾病论坛 • 上一篇    下一篇

普罗布考联合阿托伐他汀对急性冠脉综合征血脂蛋白相关磷脂酶A2的影响

杨丽1,刘寅1,刘婷2,陈倩2   

  1. 1. 天津市胸科医院
    2. 天津市胸科医院心内二科
  • 收稿日期:2011-09-21 修回日期:2011-10-11 出版日期:2012-02-15 发布日期:2012-02-15
  • 通讯作者: 杨丽

Effect of Probucol Combined with Atorvastatin on Plasma Level of Lipoprotein-associated phospholipase A2 in Patients with Acute Coronary SyndromeEffect of Probucol Combined with Atorvastatin on Plasma Level of Lipoprotein-associated phospholipase A2 in Patients with Acute Coronary Syndrome

  • Received:2011-09-21 Revised:2011-10-11 Published:2012-02-15 Online:2012-02-15

PDF (PC)

2213

摘要： 摘要 目的：评价普罗布考和阿托伐他汀联合应用对急性冠脉综合征(ACS)患者血脂及脂蛋白相关磷脂酶A2(Lp-PLA2)的影响。方法：将94例经冠脉造影证实的ACS患者随机分为2组：单药治疗组48例，予以阿托伐他汀（20 mg/d）治疗；联合治疗组46例，予以阿托伐他汀（20 mg/d）和普罗布考（500mg/d）联合治疗。分别于治疗前和治疗后6-8周检测血Lp-PLA2和血总胆固醇（TC）、三酰甘油（TG）、低密度脂蛋白胆固醇（LDL-C）、高密度脂蛋白胆固醇（HDL-C）水平并进行比较分析。结果：2组治疗前TC、TG、LDL-C、HDL-C、Lp-PLA2水平比较差异无统计学意义(P>0．05)，2组治疗后TC、TG、LDL-C、Lp-PLA2较治疗前均显著降低(P<0．01)，联合治疗组较单独治疗组TC、LDL-C、Lp-PLA2降低更为显著(P0．05)。单药治疗组治疗后HDL-C升高(P<0．O1)，联合治疗组治疗后HDL-C下降 (P<0．O1)。结论：对急性冠脉综合征患者单独应用阿伐他汀及联合普罗布考均能够有效降低TC、LDL-C、Lp-PLA2，联合治疗疗效更为显著，对稳定斑块、抗动脉粥样硬化有重要意义。

关键词: 磷脂酶A2, 普罗布考, 急性冠脉综合征, 阿托伐他汀, 脂蛋白类

Abstract: abstract Objective: To evaluate the effect of probucol and atorvastatin combined medication on blood levels of liquids and Lp-PLA2 in patients with acute coronary syndrome(ACS)．Method: A total of 94 patients with acute coronary syndrome who had been diognosised by CAG were randomly divided into two groups: single medication group(n=48)，the patients were taken atorvastatin 20 mg/d；and combined medication group(n=46)，the patients were taken atorvastatin 20 mg/d with probucol 500 mg/d.The plasma levels of Lp-PLA2 ，total cholesterol(TC)，triglyceride(TG)，low density lipoprotein-cholesterol (LDL-C) were measured in both groups before and 6-8 weeks after the medication.Then the results were compared and analysed .Resultes: There was no significant diffierence in the levels of TC、TG、LDL-C、HDL-C and Lp-PLA2 before treatment between the two roups(P>0．05)．The values of TC、TG、LDL-C and Lp-PLA2 were significantly decreased after the treatment in both two groups(P<0．01).Compared with single medication group,the value of TC, LDL-C, Lp-PLA2 were more significantly decreased in combined medication group (P0．05)．The values of HDL-C was increased after the treatment in the single medication group(P<0．O1),while decreased in the combined medication group(P<0．O1). Conclusion: The values of TC、LDL-C and Lp-PLA2 can both decrease by single atorvastatin medication or probucol and atorvastatin combined medication but more significantly by combined medication . Combined treatment played an important role in stabilizing the plaques and antiatherosclorosis in ACS patients.

Key words: phospholipases A2, probucol, acute coronary syndrome, atorvastatin, lipoproteins